Ocular Science Medical Advisory Board Expands to 28 Leaders in Ophthalmology and Optometry from Around the Country

Jacqueline Griffiths, MD, with nearly 30 years of experience, is joining a board that establishes strategies to focus on enhanced clinical solutions, products and patient outcomes for Ocular Science and affiliated PCAB-accredited 503A compounding pharmacy, OSRX.

Compounded drops save time, money

by Gary Wörtz, MD — In my opinion, compounded drops are the closest thing we have seen to the holy grail of postop pharmaceuticals in my career. Not only do compounded drops save patients money, the quality and convenience compared with both brand-name and generic formulations have piqued the interest of both providers and patients.

A Note from the CEO

2019 was an extraordinary year for Ocular Science and our affiliates OSRX and Regenerative Science. We exceeded revenue and commercial goals across the board, thanks largely to an unprecedented surge of growth from OSRX, our 503A ophthalmic compounding pharmacy, which formulates 14 combinations of medications for post-op cataract and LASIK treatment, glaucoma management, myopia control, and soon, presbyopia.

As Profits Rise, Ocular Science Promotes From Within

Ocular Science, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.

ASCRS FDA Committee Member Speaks on Access to Compounded Drugs

During an FDA public meeting this week, Damien Goldberg, MD, a member of the ASCRS FDA Committee, joined with the ophthalmic community and urged the FDA to ensure ophthalmologists have a pathway to obtain compounded drugs for office-use by allowing physicians to obtain small